The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study
Abstract
Purpose: Evaluation of treatment effects in malignant brain tumors is challenging because of the lack of reliable response predictors of tumor response. This study examines the predictive value of positron emission tomography (PET) using [18 F] fluorothymidine (FLT), an imaging biomarker of cell proliferation, in patients with recurrent malignant gliomas treated with bevacizumab in combination with irinotecan. Patients and Methods: Patients with recurrent malignant gliomas treated with biweekly cycles of bevacizumab and irinotecan were prospectively studied with FLT-PET at baseline, after 1 to 2 weeks, and after 6 weeks from start of treatment. A more than 25% reduction in tumor FLT uptake as measured by standardized uptake value was defined as a metabolic response. FLT responses were compared with response as shown by magnetic resonance imaging (MRI) and patient survival. Results: Twenty-one patients were included, and 19 were assessable for metabolic response evaluation with FLT-PET. There were nine responders (47%) and 10 nonresponders (53%). Metabolic responders survived three times as long as nonresponders (10.8 v 3.4 months; P = .003), and tended to have a prolonged progression-free survival (P = .061). Both early and later FLT-PET responses were more significant predictors of overall survival (1 to 2 weeks, P = .006; 6 weeks, P = .002), compared with the MRI responses (P = .060 for both 6-week and best responses). Conclusion: FLT-PET as an imaging biomarker seems to be predictive of overall survival in bevacizumab and irinotecan treatment of recurrent gliomas. Whether FLT-PET performed as early as 1 to 2 week after starting treatment is as predictive as the study indicates at 6 weeks warrants further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,720
Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor
Bao, S., Wu, Q., Sathornsumetee, S., Hao, Y., Li, Z., Hjelmeland, A. B., Shi, Q., McLendon, R. E., Bigner, D. D., & Rich, J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1010 · Cited by 1,345
Sample Size Tables for Clinical Studies
Machin, D., Campbell, M. J., Tan, S. B., & Tan, S. H. (2008) · Wiley eBooks · doi:10.1002/9781444300710 · Cited by 1,336
Imaging proliferation in vivo with [F-18]FLT and positron emission tomography
Shields, A. F., Grierson, J. R., Dohmen, B. M., Machulla, H.-J., Stayanoff, J. C., Lawhorn-Crews, J. M., Obradovich, J. E., Muzik, O., & Mangner, T. J. (1998) · Nature Medicine · doi:10.1038/3337 · Cited by 1,204
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 977
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen, W., Cloughesy, T. F., Kamdar, N. V., Satyamurthy, N., Bergsneider, M., Liau, L. M., Mischel, P. S., Czernin, J., Phelps, M. E., & Silverman, D. H. S. (2005) · PubMed · Cited by 437
Self-citationWillett, C. G., Boucher, Y., Duda, D. G., di Tomaso, E., Munn, L. L., Tong, R. T., Kozin, S. V., Petit, L., Jain, R. K., Chung, D. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5635 · Cited by 420
Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells.
Rasey, J. S., Grierson, J. R., Wiens, L. W., Kolb, P. D., & Schwartz, J. L. (2002) · PubMed · Cited by 406
Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
Buck, A. K., Halter, G., Schirrmeister, H., Kotzerke, J., Wurziger, I., Glatting, G., Mattfeldt, T., Neumaier, B., Reske, S. N., & Hetzel, M. (2003) · PubMed · Cited by 402
Reproducibility of metabolic measurements in malignant tumors using FDG PET.
Weber, W., Ziegler, S. I., Thödtmann, R., Hanauske, A.-R., & Schwaiger, M. (1999) · PubMed · Cited by 388
Positron emission tomography in patients with glioma a predictor of prognosis
Alavi, J. Β., Alavi, A., Chawluk, J. B., Kushner, M., Powe, J., Hickey, W. F., & Reivich, M. (1988) · Cancer · Cited by 373
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O’Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2 · Cited by 344
Imaging Angiogenesis: Applications and Potential for Drug Development
Miller, J. C., Pien, H. H., Sahani, D., Sorensen, A. G., & Thrall, J. H. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji023 · Cited by 325
Vesselle, H. J., Grierson, J. R., Muzi, M., Pugsley, J. M., Schmidt, R. A., Rabinowitz, P., Peterson, L. M., Vallières, E., & Wood, D. E. (2002) · PubMed · Cited by 300
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Pope, W. B., Lai, A., Nghiemphu, P., Mischel, P., & Cloughesy, T. F. (2006) · Neurology · doi:10.1212/01.wnl.0000208958.29600.87 · Cited by 271
Self-citationMRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Chamberlain, M. C. (2006) · Neurology · doi:10.1212/01.wnl.0000250628.10420.d8 · Cited by 264
Minn, H., Zasadny, K. R., Quint, L. E., & Wahl, R. L. (1995) · Radiology · doi:10.1148/radiology.196.1.7784562 · Cited by 260
Jacobs, A. H., Thomas, A., Kracht, L., Li, H., Dittmar, C., Garlip, G., Galldiks, N., Klein, J. C., Sobesky, J., Hilker, R., et al. (2005) · PubMed · Cited by 245
Pio, B. S., Park, C. K., Pietras, R., Hsueh, W.-A., Satyamurthy, N., Pegram, M. D., Czernin, J., Phelps, M. E., & Silverman, D. H. S. (2006) · Molecular Imaging and Biology · doi:10.1007/s11307-005-0029-9 · Cited by 223
Self-citationPositron emission tomography imaging of brain tumors
Wong, T. Z., van der Westhuizen, G. J., & Coleman, R. E. (2002) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(02)00033-3 · Cited by 207
[18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors
Choi, S. J., Kim, J. S., Kim, J. H., Oh, S. J., Lee, J. G., Kim, C. J., Ra, Y. S., Yeo, J. S., Ryu, J. S., & Moon, D. H. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1742-3 · Cited by 189
Chen, H. X., Mooney, M., Boron, M., Vena, D., Mosby, K., Grochow, L., Jaffe, C., Rubinstein, L., Zwiebel, J., & Kaplan, R. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1573 · Cited by 186
Molecular Imaging of Proliferation in Malignant Lymphoma
Buck, A. K., Bommer, M., Stilgenbauer, S., Juweid, M., Glatting, G., Schirrmeister, H., Mattfeldt, T., Tepsic, D., Bunjes, D., Mottaghy, F. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1955 · Cited by 185
Wagner, M., Seitz, U., Buck, A. K., Neumaier, B., Schultheiß, S., Bangerter, M., Bommer, M., Leithäuser, F., Wawra, E., Munzert, G. M., et al. (2003) · PubMed · Cited by 178
Yap, C. S., Czernin, J., Fishbein, M. C., Cameron, R. B., Schiepers, C., Phelps, M. E., & Weber, W. A. (2006) · Chest · doi:10.1378/chest.129.2.393 · Cited by 166
Self-citationRationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Park, J. W., Kerbel, R. S., Kelloff, G. J., Barrett, J. C., Chabner, B. A., Parkinson, D. R., Peck, J., Ruddon, R. W., Sigman, C. C., & Slamon, D. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0785 · Cited by 159
Masi, A., Becchetti, A., Cassulini, R. R., Polvani, S., Hofmann, G., Buccoliero, A. M., Paglierani, M., Pollo, B., Taddei, G. L., Gallina, P., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602775 · Cited by 154
In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography
Francis, D., Freeman, A., Visvikis, D., Costa, D. C., Luthra, S. K., Novelli, M. R., Taylor, I., & Ell, P. J. (2003) · Gut · doi:10.1136/gut.52.11.1602 · Cited by 134
Toyohara, J., Waki, A., Takamatsu, S., Yonekura, Y., Magata, Y., & Fujibayashi, Y. (2002) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(02)00286-x · Cited by 130
Chemotherapy response criteria in malignant glioma
Grant, R., Liang, B. C., Slattery, J. M. A., Greenberg, H. S., & Junck, L. (1997) · Neurology · doi:10.1212/wnl.48.5.1336 · Cited by 67
Ignoffo, R. J. (2004) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/61.suppl_5.s21 · Cited by 67
Cited by
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Skeletal PET with18F-Fluoride: Applying New Technology to an Old Tracer
Grant, F. D., Fahey, F. H., Packard, A. B., Davis, R. T., Alavi, A., & Treves, S. T. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037200 · Cited by 520
Sorensen, A. G., Batchelor, T. T., Zhang, W.-T., Chen, P.-J., Yeo, P., Wang, M., Jennings, D., Wen, P. Y., Lahdenranta, J., Ancukiewicz, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0814 · Cited by 394
Pseudoprogression and pseudoresponse in the treatment of gliomas
Brandsma, D., & van den Bent, M. J. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328332363e · Cited by 378
Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas
Dhermain, F. G., Hau, P., Lanfermann, H., Jacobs, A. H., & van den Bent, M. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70181-2 · Cited by 368
Metadata
- Authors
- Chen, W., Delaloye, S., Silverman, D. H. S., Geist, C., Czernin, J., Sayre, J., Satyamurthy, N., Pope, W., Lai, A., Phelps, M. E., & Cloughesy, T.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-10-20
- Volume
- 25
- Issue
- 30
- Pages
- 4714-4721
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2166921825
- Cited by
- 393
- References
- 42
- FWCI
- 18.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.